STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Camp4 Therapeutics Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
0001736730false00017367302025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
CAMP4 THERAPEUTICS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-4236581-1152476
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
One Kendall Square
Building 1400 West, 3rd Floor
Cambridge, MA
02139
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code): (617) 651-8867
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.0001 per shareCAMPThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2025, CAMP4 Therapeutics Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
Press release issued by CAMP4 Therapeutics Corporation on November 6, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CAMP4 THERAPEUTICS CORPORATION
By:/s/ Josh Mandel-Brehm
Name: Josh Mandel-Brehm
Title:   President and Chief Executive Officer
Date: November 6, 2025

FAQ

What did CAMP4 (CAMP) announce in this 8-K?

CAMP4 furnished a press release with financial results for the quarter ended September 30, 2025, as Exhibit 99.1 under Item 2.02.

Which period do the CAMP4 results cover?

The results cover the quarter ended September 30, 2025.

Is the CAMP4 press release considered filed with the SEC?

No. The information is furnished, not filed, and is not subject to Section 18 liabilities, except if later incorporated by reference.

Where can I find the detailed CAMP4 results?

They are in Exhibit 99.1 to the 8-K.

What is CAMP4’s trading symbol and exchange?

The common stock trades as CAMP on The Nasdaq Global Market.

What item of Form 8-K does this relate to?

It relates to Item 2.02, Results of Operations and Financial Condition.
Camp4 Therapeutics Corp.

NASDAQ:CAMP

CAMP Rankings

CAMP Latest News

CAMP Latest SEC Filings

CAMP Stock Data

89.72M
37.19M
35.19%
51.76%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE